“Based on ARK's research, the enterprise value of companies focused on precision therapies could appreciate 28% at an annual rate during the next seven years, from ~$820 billion in 2023 to ~$4.5 trillion by 2030, as multiomic tools and technology reduce research and development spending per drug by more than 25%.”

Resolves in 2030 on the aggregate enterprise value of precision-therapy companies versus the ~$4.5 trillion projection.